Literature DB >> 11267734

Perception of teratogenic risk of common medicines.

E Sanz1, T Gómez-López, M J Martínez-Quintas.   

Abstract

OBJECTIVE: To assess the perception of the teratogenic risk of common medication by professionals and lay people. STUDY
DESIGN: A visual-analogue scale was used to measure the perceived percentage of mothers who will deliver a child with a malformation, including those exposed to a list of drugs. Fifteen general practitioners, 10 gynaecologists, 106 pre-clinical students, 150 students in their clinical training, 81 pregnant women and 63 non-pregnant women were interviewed.
RESULTS: The perception of the teratogenic risk related to medication used in pregnancy was higher than the recognised risk in all groups, and for all drugs. The risk associated with safe medications was perceived to be higher by non-pregnant women as compared with the pregnant women. Pregnant women perceived the medication associated risk to be higher than physicians did for all drugs included in the questionnaire.
CONCLUSIONS: The high and unrealistic perception of teratogenic risk amongst women and health professionals may lead to abortions of otherwise wanted and healthy children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11267734     DOI: 10.1016/s0301-2115(00)00375-4

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  28 in total

1.  Birth defects, causal attributions, and ethnicity in the national birth defects prevention study.

Authors:  Amy P Case; Marjorie Royle; Angela E Scheuerle; Suzan L Carmichael; Karen Moffitt; Tunu Ramadhani
Journal:  J Genet Couns       Date:  2014-03-29       Impact factor: 2.537

2.  Drug use in pregnancy--physicians' evaluation of quality and clinical impact of drug information centres.

Authors:  Sofia Kristina Frost Widnes; Jan Schjøtt
Journal:  Eur J Clin Pharmacol       Date:  2008-12-04       Impact factor: 2.953

3.  Drugs and Birth Defects: a knowledge database providing risk assessments based on national health registers.

Authors:  Ulrika Nörby; Karin Källén; Birgit Eiermann; Seher Korkmaz; Birger Winbladh; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2012-09-26       Impact factor: 2.953

4.  Counselling pregnant women at the crossroads of Europe and Asia: effect of Teratology Information Service in Turkey.

Authors:  Yusuf Cem Kaplan; Barış Karadaş; Gözde Küçüksolak; Bartu Ediz; Ömer Demir; Kaan Sozmen; Hedvig Nordeng
Journal:  Int J Clin Pharm       Date:  2017-06-19

5.  Clinical decision support to promote safe prescribing to women of reproductive age: a cluster-randomized trial.

Authors:  Eleanor Bimla Schwarz; Sara M Parisi; Steven M Handler; Gideon Koren; Elan D Cohen; Grant J Shevchik; Gary S Fischer
Journal:  J Gen Intern Med       Date:  2012-07       Impact factor: 5.128

6.  Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women.

Authors:  Eleanor Bimla Schwarz; Debbie A Postlethwaite; Yun-Yi Hung; Mary Anne Armstrong
Journal:  Ann Intern Med       Date:  2007-09-18       Impact factor: 25.391

7.  Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs.

Authors:  Kathleen Uhl; Dianne L Kennedy; Sandra L Kweder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  Teratogenic risk perception and confidence in use of medicines in pairs of pregnant women and general practitioners based on patient information leaflets.

Authors:  Sofia Frost Widnes; Jan Schjøtt; Geir Egil Eide; Anne Gerd Granas
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

9.  Views and experiences of suicidal ideation during pregnancy and the postpartum: findings from interviews with maternal care clinic patients.

Authors:  Karen M Tabb; Amelia R Gavin; Yuqing Guo; Hsiang Huang; Kate Debiec; Wayne Katon
Journal:  Women Health       Date:  2013

10.  Perception of risk regarding the use of medications and other exposures during pregnancy.

Authors:  Hedvig Nordeng; Eivind Ystrøm; Adrienne Einarson
Journal:  Eur J Clin Pharmacol       Date:  2009-10-20       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.